AHA blog: Flawed report aims to bury role of insurers in high drug costs
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to their own specialty pharmacies, write AHA’s Mark Howell, director of policy and patient safety, and Bharath Krishnamurthy, director of health analytics and policy. “The report, which is fraught with half-truths and methodological flaws, is nothing more than a blatant attempt to deflect from the obvious — insurance companies continue to raise premiums for their enrollees and employer clients while pocketing billions in profits.” READ MORE
Related News Articles
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
The Congressional Budget Office Dec. 5 informed Congress that 2.2 million consumers would lose their health insurance in 2026 if enhanced premium subsidies are…
Headline
A $2.8 billion settlement from Blue Cross Blue Shield to health care providers resolving a 12-year antitrust lawsuit received preliminary approval yesterday…
Headline
The Department of Health and Human Services' Government Accountability Office Nov. 14 released a report that determined the private health insurance market…
Headline
In comments Nov. 11 to the Centers for Medicare & Medicaid Services on its Notice of Benefit and Payment Parameters for 2026, the AHA expressed support for…
Headline
Beginning Nov. 1 through Jan. 15, individuals and families can enroll in or change their health coverage options through the Health Insurance Marketplace. The…